Stockreport

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat [Seeking Alpha]

Sagimet Biosciences Inc.  (SGMT) 
PDF Follow Summary Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation [Read more]